热门资讯> 正文

FDA接受ozeikibart的Inhibrx BLA

2026-06-15 22:34

The US FDA has accepted for review Inhibrx Biosciences' (INBX) BLA for ozekibart to treat unresectable or metastatic conventional chondrosarcoma.
The application has an action date of April 14, 2027.
There are currently no FDA-approved therapies for the rare bone cancer.
The BLA is supported by data from the ChonDRAgon study that met its primary endpoint of a statistically significant median progression-free survival for individuals given ozekibart compared to placebo.
Ozekibart is considered a tetravalent death receptor 5 (DR5) agonist antibody.

More on Inhibrx Biosciences

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data
Inhibrx Biosciences GAAP EPS of -$2.15
Inhibrx rises on upcoming interim mid-stage data for head and neck cancer asset
Seeking Alpha’s Quant Rating on Inhibrx Biosciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。